Known targets — ChEMBL curated mechanism
ABL1BRAFDDR2EPHA2FGFR1FGFR2FLT1FLT4FRKKDRKITMAPK11NTRK1PDGFRAPDGFRBRAF1RETTEK
The experimentally established mechanism targets of Regorafenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 known ✓ | P04049 | 12/20 | 1.00 |
| ▸ | BRAF known ✓ | P15056 | 7/20 | 1.00 |
| ▸ | KDR known ✓ | P35968 | 6/20 | 1.00 |
| ▸ | RET known ✓ | P07949 | 3/20 | 1.00 |
| ▸ | ABL1 known ✓ | P00519 | 2/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 1.00 |
| ▸ | FGFR1 known ✓ | P11362 | 2/20 | 1.00 |
| ▸ | PDGFRA known ✓ | P16234 | 2/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 2/20 | 1.00 |
| ▸ | EPHA2 known ✓ | P29317 | 2/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 1.00 |
| ▸ | TEK known ✓ | Q02763 | 2/20 | 1.00 |
| ▸ | MAPK11 known ✓ | Q15759 | 2/20 | 1.00 |
| ▸ | DDR2 known ✓ | Q16832 | 2/20 | 1.00 |
| ▸ | NTRK1 known ✓ | P04629 | 1/20 | 0.83 |
| ▸ | FGFR2 known ✓ | P21802 | 1/20 | 0.83 |
| ▸ | FRK known ✓ | P42685 | 1/20 | 0.83 |
| ▸ | RIPK2 | O43353 | 3/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Regorafenib SCHEMBL29351376 | 1.00 | RAF1 (1.00) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL29349808 | 1.00 | RAF1 (1.00) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL29496390 | 0.99 | RAF1 (0.98) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL2554008 | 0.99 | RAF1 (0.98) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL29555444 | 0.99 | RAF1 (0.98) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL2555101 | 0.99 | RAF1 (0.98) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL2552684 | 0.97 | RAF1 (0.93) | RAF1BRAFKDRRETRIPK2 | |
| Regorafenib SCHEMBL30433607 | 0.94 | RAF1 (0.89) | RAF1BRAFKDRRETRIPK2 | |
| SCHEMBL5086313 | 0.93 | RAF1 (0.87) | RAF1BRAFKDRRETRIPK2 | |
| SCHEMBL22627130 | 0.92 | RAF1 (0.85) | RAF1BRAFKDRRETRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 646 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11951166-B2 | Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-09 | — | — | US | claimed |
| US-11723929-B2 | Methods of improving cell-based therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-15 | — | — | US | claimed |
| EP-2786750-B2 | AGENT FOR REDUCING ADVERSE SIDE EFFECTS OF KINASE INHIBITOR | EA PHARMA CO LTD (JP) | 2023-06-28 | — | — | EP | claimed |
| US-11517622-B2 | Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer | BAYER HEALTHCARE LLC (US) | 2022-12-06 | — | — | US | claimed |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-05-24 | — | — | US | claimed |
| US-20220133888-A1 | COMBINATION OF REGORAFENIB AND PD-1/PD-L1(2) INHIBITORS FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-05 | — | — | US | claimed |
| US-20210145891-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-05-20 | — | — | US | claimed |
| WO-2018231702-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-12-20 | — | — | WO | claimed |
| US-10144710-B2 | Process for the preparation of 4-[-({[4-choloro-3(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide and its polymorphs thereof | MSN LABORATORIES PRIVATE LIMITED (IN) | 2018-12-04 | — | — | US | claimed |
| US-20180311220-A1 | TREATMENT OF CANCERS WITH ACQUIRED RESISTANCE TO KIT INHIBITORS | BAYER HEALTHCARE LLC (US) | 2018-11-01 | — | — | US | claimed |
| EP-1663978-A2 | FLUORO SUBSTITUTED OMEGA-CARBOXYARYL DIPHENYL UREA FOR THE TREATMENT AND PREVENTION OF DISEASES AND CONDITIONS | Bayer Pharmaceuticals Corporation (US) | 2006-06-07 | — | — | EP | claimed |
| EP-1636585-A2 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | Bayer Pharmaceuticals Corporation (US) | 2006-03-22 | — | — | EP | claimed |
| US-20060058358-A1 | Pharmaceutical compositions for the treatment of hyper-proliferative disorders | BAYER HEALTHCARE LLC | 2006-03-16 | — | — | US | claimed |
| EP-1626714-A2 | DIARYL UREAS FOR DISEASES MEDIATED BY PDGFR | Bayer Pharmaceuticals Corporation (US) | 2006-02-22 | — | — | EP | claimed |
| US-20050059703-A1 | Treating, ameliorating, preventing, or modulating restenosis following angioplastic surgery, injure the vascular system; a salt of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea; intravascular stent is impregnated with the compound to inhibit restenosis | BAYER HEALTHCARE LLC | 2005-03-17 | — | — | US | claimed |
| US-20050038080-A1 | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions | BAYER HEALTHCARE LLC | 2005-02-17 | — | — | US | claimed |
| US-20050032798-A1 | 2-Oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatory disorders | BAYER HEALTHCARE LLC | 2005-02-10 | — | — | US | claimed |
| WO-2005009961-A2 | FLUORO SUBSTITUTED OMEGA-CARBOXYARYL DIPHENYL UREA FOR THE TREATMENT AND PREVENTION OF DISEASES AND CONDITIONS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-02-03 | — | — | WO | claimed |
| WO-2005000284-A2 | DIARYL UREAS FOR DISEASES MEDIATED BY PDGFR | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-01-06 | — | — | WO | claimed |
| WO-2004113274-A2 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-12-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059703-A1 | Treating, ameliorating, preventing, or modulating restenosis following angioplastic surgery, injure the vascular system; a salt of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea; intravascular stent is impregnated with the compound to inhibit restenosis | PDGFRB, PDGFRA, PDGFA | RAF1 761/4885BRAF 1489/4885KDR 14/4885 |
| US-10144710-B2 | Process for the preparation of 4-[-({[4-choloro-3(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide and its polymorphs thereof | CYP4X1, CYP4B1, CYP4F12 | RAF1 4071/4885BRAF 3527/4885KDR 4062/4885 |
| US-11723929-B2 | Methods of improving cell-based therapy | EPHX1, EPHX2, NCEH1 | RAF1 3766/4885BRAF 3924/4885KDR 861/4885 |
| US-20060058358-A1 | Pharmaceutical compositions for the treatment of hyper-proliferative disorders | MKI67, CCNA1, CCND2 | RAF1 147/4885BRAF 102/4885KDR 2482/4885 |
| US-20050032798-A1 | 2-Oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatory disorders | HYOU1, HIF1A, HCAR2 | RAF1 4134/4885BRAF 4094/4885KDR 62/4885 |
| US-11951166-B2 | Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer | PDCD1, CD274, PDCD1LG2 | RAF1 18/4885BRAF 9/4885KDR 1071/4885 |
| US-20220133888-A1 | COMBINATION OF REGORAFENIB AND PD-1/PD-L1(2) INHIBITORS FOR TREATING CANCER | PDCD1, CD274, PDCD1LG2 | RAF1 18/4885BRAF 9/4885KDR 1071/4885 |
| US-20180311220-A1 | TREATMENT OF CANCERS WITH ACQUIRED RESISTANCE TO KIT INHIBITORS | KIT, NRAS, KRAS | RAF1 74/4885BRAF 20/4885KDR 427/4885 |
| US-20210145891-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | EPHX1, EPHX2, NCEH1 | RAF1 3766/4885BRAF 3924/4885KDR 861/4885 |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, MAPK1 | RAF1 223/4885BRAF 477/4885KDR 1131/4885 |
| US-20050038080-A1 | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions | FLT4, FLT1, PDGFRB | RAF1 14/4885BRAF 7/4885KDR 5/4885 |
| US-11517622-B2 | Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer | PDCD1, CD274, PDCD1LG2 | RAF1 18/4885BRAF 9/4885KDR 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.